Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Research

A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer

Authors: Yang Fu, Shanshan Sun, Jianbin Bi, Chuize Kong, Lei Yin

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Bladder cancer (BC) is the ninth most common malignant tumor. We constructed a risk signature using immune-related gene pairs (IRGPs) to predict the prognosis of BC patients.

Methods

The mRNA transcriptome, simple nucleotide variation and clinical data of BC patients were downloaded from The Cancer Genome Atlas (TCGA) database (TCGA-BLCA). The mRNA transcriptome and clinical data were also extracted from Gene Expression Omnibus (GEO) datasets (GSE31684). A risk signature was built based on the IRGPs. The ability of the signature to predict prognosis was analyzed with survival curves and Cox regression. The relationships between immunological parameters [immune cell infiltration, immune checkpoints, tumor microenvironment (TME) and tumor mutation burden (TMB)] and the risk score were investigated. Finally, gene set enrichment analysis (GSEA) was used to explore molecular mechanisms underlying the risk score.

Results

The risk signature utilized 30 selected IRGPs. The prognosis of the high-risk group was significantly worse than that of the low-risk group. We used the GSE31684 dataset to validate the signature. Close relationships were found between the risk score and immunological parameters. Finally, GSEA showed that gene sets related to the extracellular matrix (ECM), stromal cells and epithelial-mesenchymal transition (EMT) were enriched in the high-risk group. In the low-risk group, we found a number of immune-related pathways in the enriched pathways and biofunctions.

Conclusions

We used a new tool, IRGPs, to build a risk signature to predict the prognosis of BC. By evaluating immune parameters and molecular mechanisms, we gained a better understanding of the mechanisms underlying the risk signature. This signature can also be used as a tool to predict the effect of immunotherapy in patients with BC.

Available only for authorised users

SEER cancer statistics review, 1975–2016, National Cancer Institute. Bethesda. https://seer.cancer.gov/csr/based on November 2018 SEER data submission, posted to the SEER web site.

Nabavizadeh R, Bobrek K, Master VA. Risk stratification for bladder cancer: biomarkers of inflammation and immune activation. Urol Oncol. 2020;38(9):706–12. https://doi.org/10.1016/j.urolonc.2020.04.006.CrossRefPubMed

Li F, Guo H, Wang Y, Liu B, Zhou H. Profiles of tumor-infiltrating immune cells and prognostic genes associated with the microenvironment of bladder cancer. Int Immunopharmacol. 2020;85:106641. https://doi.org/10.1016/j.intimp.2020.106641.CrossRefPubMed

Rouanne M, Roumiguié M, Houédé N, Masson-Lecomte A, Colin P, Pignot G, et al. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. World J Urol. 2018;36(11):1727–40. https://doi.org/10.1007/s00345-018-2332-5.CrossRefPubMed

von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8. https://doi.org/10.1200/JCO.2005.07.757.CrossRefPubMed

Duan S, Wang P, Liu F, Huang H, An W, Pan S, et al. Novel immune-risk score of gastric cancer: a molecular prediction model combining the value of immune-risk status and chemosensitivity. Cancer Med. 2019;8(5):2675–85. https://doi.org/10.1002/cam4.2077.CrossRefPubMedPubMedCentral

Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261–7. https://doi.org/10.1016/j.coi.2013.03.004.CrossRefPubMed

Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–45. https://doi.org/10.1038/nm.3909.CrossRefPubMedPubMedCentral

Carter BW, Halpenny DF, Ginsberg MS, Papadimitrakopoulou VA, de Groot PM. Immunotherapy in Non-Small Cell Lung Cancer Treatment: Current Status and the Role of Imaging. Journal of thoracic imaging. 2017;32(5):300-12. https://doi.org/10.1097/RTI.0000000000000291.

10.

Lin P, Guo YN, Shi L, Li XJ, Yang H, He Y, et al. Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer. Aging (Albany NY). 2019;11(2):480-500. https://doi.org/10.18632/aging.101754.

11.

Arora S, Velichinskii R, Lesh RW, Ali U, Kubiak M, Bansal P, et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv Ther. 2019;36(10):2638–78. https://doi.org/10.1007/s12325-019-01051-z.CrossRefPubMedPubMedCentral

12.

Kresowik TP, Griffith TS. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy. 2009;1(2):281–8. https://doi.org/10.2217/1750743X.1.2.281.CrossRefPubMed

13.

Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15(10):615–25. https://doi.org/10.1038/s41585-018-0055-4.CrossRefPubMed

14.

Steinberg RL, Nepple KG, Velaer KN, Thomas LJ, O'Donnell MA. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer. Urol Oncol. 2017;35(12):670.e677–14.CrossRef

15.

Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90–5. https://doi.org/10.1016/S0022-5347(05)64043-8.CrossRefPubMed

16.

Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992;147(3):596–600. https://doi.org/10.1016/S0022-5347(17)37316-0.CrossRefPubMed

17.

Roufas C, Chasiotis D, Makris A, Efstathiades C, Dimopoulos C, Zaravinos A. The expression and prognostic impact of immune cytolytic activity-related markers in human malignancies: a comprehensive meta-analysis. Front Oncol. 2018;8:27. https://doi.org/10.3389/fonc.2018.00027.CrossRefPubMedPubMedCentral

18.

Gust KM, Rebhan K, Resch I, Shariat SF, Necchi A. Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer. Curr Opin Urol. 2020;30(4):547–56. https://doi.org/10.1097/MOU.0000000000000783.CrossRefPubMed

19.

Zhang C, Li Z, Qi F, Hu X, Luo J. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma. Ann Transl Med. 2019;7(22):648. https://doi.org/10.21037/atm.2019.10.84.CrossRefPubMedPubMedCentral

20.

Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han CT, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. J Immunother Cancer. 2019;7(1):180. https://doi.org/10.1186/s40425-019-0659-0.CrossRefPubMedPubMedCentral

21.

Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019;30(9):1479–86. https://doi.org/10.1093/annonc/mdz197.CrossRefPubMedPubMedCentral

22.

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–608. https://doi.org/10.1158/1535-7163.MCT-17-0386.CrossRefPubMedPubMedCentral

23.

Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J, et al. ImmPort: disseminating data to the public for the future of immunology. Immunologic research. 2014;58(2-3):234-9. https://doi.org/10.1007/s12026-014-8516-1.

24.

Kang K, Xie F, Mao J, Bai Y, Wang X. Significance of tumor mutation burden in immune infiltration and prognosis in cutaneous melanoma. Front Oncol. 2020;10:573141. https://doi.org/10.3389/fonc.2020.573141.CrossRefPubMedPubMedCentral

25.

Sun XY, Yu SZ, Zhang HP, Li J, Guo WZ, Zhang SJ. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma. Cancer Med. 2020;9(8):2868–78. https://doi.org/10.1002/cam4.2921.CrossRefPubMedPubMedCentral

26.

Luo J, Liu P, Wang L, Huang Y, Wang Y, Geng W, et al. Establishment of an immune-related gene pair model to predict colon adenocarcinoma prognosis. BMC Cancer. 2020;20(1):1071. https://doi.org/10.1186/s12885-020-07532-7.CrossRefPubMedPubMedCentral

27.

Qiu H, Hu X, He C, Yu B, Li Y, Li J. Identification and validation of an individualized prognostic signature of bladder cancer based on seven immune related genes. Front Genet. 2020;11:12. https://doi.org/10.3389/fgene.2020.00012.CrossRefPubMedPubMedCentral

28.

Zhu J, Wang H, Ma T, He Y, Shen M, Song W, et al. Identification of immune-related genes as prognostic factors in bladder cancer. Sci Rep. 2020;10(1):19695. https://doi.org/10.1038/s41598-020-76688-w.CrossRefPubMedPubMedCentral

29.

Wang J, Shen C, Dong D, Zhong X, Wang Y, Yang X. Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer. Int Immunopharmacol. 2021;90:107146. https://doi.org/10.1016/j.intimp.2020.107146.CrossRefPubMed

30.

Xing Q, Liu S, Jiang S, Li T, Wang Z, Wang Y. Prognostic model of 10 immune-related genes and identification of small molecule drugs in bladder urothelial carcinoma (BLCA). Transl Androl Urol. 2020;9(5):2054–70. https://doi.org/10.21037/tau-20-696.CrossRefPubMedPubMedCentral

31.

Wu Y, Zhang L, He S, Guan B, He A, Yang K, et al. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer. Aging (Albany NY). 2020;12(22):23306–25. https://doi.org/10.18632/aging.104115.CrossRefPubMedCentral

32.

Deng Y, Hong X, Yu C, Li H, Wang Q, Zhang Y, et al. Preclinical analysis of novel prognostic transcription factors and immune-related gene signatures for bladder cancer via TCGA-based bioinformatic analysis. Oncol Lett. 2021;21(5):344. https://doi.org/10.3892/ol.2021.12605.CrossRefPubMedPubMedCentral

33.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7. https://doi.org/10.1038/nmeth.3337.CrossRefPubMedPubMedCentral

34.

Ye L, Zhang T, Kang Z, Guo G, Sun Y, Lin K, et al. Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer. Front Immunol. 2019;10:2368. https://doi.org/10.3389/fimmu.2019.02368.CrossRefPubMedPubMedCentral

35.

Zhang L, Zhu P, Tong Y, Wang Y, Ma H, Xia X, et al. An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma. Onco Targets Ther. 2019;12:7005–14. https://doi.org/10.2147/OTT.S200191.CrossRefPubMedPubMedCentral

36.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612. https://doi.org/10.1038/ncomms3612.CrossRefPubMed

37.

Li B, Geng R, Wu Q, Yang Q, Sun S, Zhu S, et al. Alterations in immune-related genes as potential marker of prognosis in breast cancer. Front Oncol. 2020;10:333. https://doi.org/10.3389/fonc.2020.00333.CrossRefPubMedPubMedCentral

38.

Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. https://doi.org/10.1093/nar/28.1.27.CrossRefPubMedPubMedCentral

39.

Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–75. https://doi.org/10.1016/j.eururo.2016.06.020.CrossRefPubMed

40.

Wołącewicz M, Hrynkiewicz R, Grywalska E, Suchojad T, Leksowski T, Roliński J, et al. Immunotherapy in bladder cancer: current methods and future perspectives. Cancers. 2020;12(5):1181.CrossRefPubMedCentral

41.

Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008;179(1):53–6. https://doi.org/10.1016/j.juro.2007.08.122.CrossRefPubMed

42.

Seidl C. Targets for therapy of bladder cancer. Semin Nucl Med. 2020;50(2):162–70. https://doi.org/10.1053/j.semnuclmed.2020.02.006.CrossRefPubMed

43.

Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58–67. https://doi.org/10.1016/j.ctrv.2017.01.007.CrossRefPubMed

44.

Katz H, Wassie E, Alsharedi M. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer. Med Oncol. 2017;34(10):170.CrossRefPubMed

45.

Cunha LL, Marcello MA, Rocha-Santos V, Ward LS. Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way. Endocr Relat Cancer. 2017;24(12):T261-81. https://doi.org/10.1530/ERC-17-0222.

46.

Popovic A, Jaffee EM, Zaidi N. Emerging strategies for combination checkpoint modulators in cancer immunotherapy. The Journal of clinical investigation. 2018;128(8):3209-18. https://doi.org/10.1172/jci120775

47.

Kobold S, Pantelyushin S, Rataj F, Vom Berg J. Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. Front Oncol 2018;8:285-93. https://doi.org/10.3389/fonc.2018.00285.

48.

Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J. Targeting advanced urothelial carcinoma-developing strategies. Curr Opin Oncol. 2019;31(3):207–15. https://doi.org/10.1097/CCO.0000000000000532.CrossRefPubMed

49.

Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death Ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119–25. https://doi.org/10.1200/JCO.2016.67.9761.CrossRefPubMedPubMedCentral

50.

Li B, Cui Y, Diehn M, Li R. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol. 2017;3(11):1529–37. https://doi.org/10.1001/jamaoncol.2017.1609.CrossRefPubMedPubMedCentral

51.

Ouyang W, Ren L, Liu G, Chi X, Wei H. LncRNA MIR4435-2HG predicts poor prognosis in patients with colorectal cancer. PeerJ. 2019;7:e6683. https://doi.org/10.7717/peerj.6683.CrossRefPubMedPubMedCentral

52.

Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet. 2010;11(10):733–9. https://doi.org/10.1038/nrg2825.CrossRefPubMed

53.

Eddy JA, Sung J, Geman D, Price ND. Relative expression analysis for molecular cancer diagnosis and prognosis. Technol Cancer Res Treat. 2010;9(2):149–59. https://doi.org/10.1177/153303461000900204.CrossRefPubMed

54.

Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G, et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol. 2012;30(12):1288–95. https://doi.org/10.1200/JCO.2011.39.5814.CrossRefPubMed

55.

Peng PL, Zhou XY, Yi GD, Chen PF, Wang F, Dong WG. Identification of a novel gene pairs signature in the prognosis of gastric cancer. Cancer Med. 2018;7(2):344–50. https://doi.org/10.1002/cam4.1303.CrossRefPubMed

56.

Cheah MT, Chen JY, Sahoo D, Contreras-Trujillo H, Volkmer AK, Scheeren FA, et al. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci U S A. 2015;112(15):4725–30. https://doi.org/10.1073/pnas.1424795112.CrossRefPubMedPubMedCentral

57.

Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, et al. A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis. Cancer Discov. 2017;7(7):694–703. https://doi.org/10.1158/2159-8290.CD-16-1184.CrossRefPubMed

58.

Wei R, Rodrìguez RA, Mullor M, Tan Z, Gui Y, Hu J, et al. Analyzing the prognostic value of DKK1 expression in human cancers based on bioinformatics. Ann Transl Med. 2020;8(8):552. https://doi.org/10.21037/atm-20-3263.CrossRefPubMedPubMedCentral

59.

Bukan N, Sözen S, Coskun U, Sancak B, Günel N, Bozkirli I, et al. Serum interleukin-18 and nitric oxide activity in bladder carcinoma. Eur Cytokine Netw. 2003;14(3):163–7.PubMed

60.

Qin Z, Wang Y, Tang J, Zhang L, Li R, Xue J, et al. High LINC01605 expression predicts poor prognosis and promotes tumor progression via up-regulation of MMP9 in bladder cancer. Biosci Rep. 2018;38(5):BSR20180562.CrossRefPubMedPubMedCentral

61.

Liu F, Zhang H, Xie F, Tao D, Xiao X, Huang C, et al. Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis. Oncogene. 2020;39(8):1696–709. https://doi.org/10.1038/s41388-019-1092-z.CrossRefPubMed

62.

Matarazzo S, Melocchi L, Rezzola S, Grillo E, Maccarinelli F, Giacomini A, et al. Long pentraxin-3 follows and modulates bladder cancer progression. Cancers. 2019;11(9):1277.CrossRefPubMedCentral

63.

Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, et al. Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell. 2020;181(7):1612–1625.e13. https://doi.org/10.1016/j.cell.2020.05.017.CrossRefPubMedPubMedCentral

64.

Hartana CA, Ahlén Bergman E, Zirakzadeh AA, Krantz D, Winerdal ME, Winerdal M, et al. Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFβ2 mediated pathway. PLoS One. 2018;13(7):e0200079. https://doi.org/10.1371/journal.pone.0200079.CrossRefPubMedPubMedCentral

65.

Liu J, Duan X. PA-MSHA induces apoptosis and suppresses metastasis by tumor associated macrophages in bladder cancer cells. Cancer Cell Int. 2017;17(1):76. https://doi.org/10.1186/s12935-017-0445-3.CrossRefPubMedPubMedCentral

66.

Li P, Cao J, Li J, Yao Z, Han D, Ying L, et al. Identification of prognostic biomarkers associated with stromal cell infiltration in muscle-invasive bladder cancer by bioinformatics analyses. Cancer Med. 2020;9(19):7253–67. https://doi.org/10.1002/cam4.3372.CrossRefPubMedPubMedCentral

67.

Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 2019;36(3):171–98. https://doi.org/10.1007/s10585-019-09966-1.CrossRefPubMed

68.

Luo Y, Zeng G, Wu S. Identification of microenvironment-related prognostic genes in bladder cancer based on gene expression profile. Front Genet. 2019;10:1187. https://doi.org/10.3389/fgene.2019.01187.CrossRefPubMedPubMedCentral

69.

Shintani Y, Hollingsworth MA, Wheelock MJ, Johnson KR. Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res. 2006;66(24):11745–53. https://doi.org/10.1158/0008-5472.CAN-06-2322.CrossRefPubMed

70.

Torzilli PA, Bourne JW, Cigler T, Vincent CT. A new paradigm for mechanobiological mechanisms in tumor metastasis. Semin Cancer Biol. 2012;22(5–6):385–95. https://doi.org/10.1016/j.semcancer.2012.05.002.CrossRefPubMedPubMedCentral

71.

Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37. https://doi.org/10.1038/nm.3394.CrossRefPubMedPubMedCentral

72.

Hynes RO. The extracellular matrix: not just pretty fibrils. Science. 2009;326(5957):1216–9.CrossRefPubMedPubMedCentral

73.

Li D, Zhang Y, Zhang H, Zhan C, Li X, Ba T, et al. CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2018;37(1):46. https://doi.org/10.1186/s13046-018-0699-1.CrossRefPubMedPubMedCentral

74.

Yang TY, Wu ML, Chang CI, Liu CI, Cheng TC, Wu YJ. Bornyl cis-4-hydroxycinnamate suppresses cell metastasis of melanoma through FAK/PI3K/Akt/mTOR and MAPK signaling pathways and inhibition of the epithelial-to-mesenchymal transition. Int J Mol Sci. 2018;19(8):2152.CrossRefPubMedCentral

75.

Kong DB, Chen F, Sima N. Focal adhesion kinases crucially regulate TGFβ-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin. Onco Targets Ther. 2017;10:1783–92. https://doi.org/10.2147/OTT.S122463.CrossRefPubMedPubMedCentral

Title: A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer
Authors: Yang Fu
Shanshan Sun
Jianbin Bi
Chuize Kong
Lei Yin
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08486-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Guy’s and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database

Prevalence and associations of axillary web syndrome in Asian women after breast cancer surgery undergoing a community-based cancer rehabilitation program

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma

Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer